The IBS-C drugs market of North America is expected to grow at CAGR of 7.30% over the forecast period of 2017-2025.The North America drugs market was valued at US$439.5 in the year 2016 and worth optimize up to US $825.07 by the end of 2025.

The IBS-C drugs market of Asia-Pacific is expected to grow at CAGR of 6.29% during the forecast period of 2017-2025. The Asia-Pacific drugs market of IBS-C generated revenue of US$121.8 in the year 2016 and expected to generate revenue of US $210.28 by the end of 2025.

The IBS-C is a chronic functional GI disorder that afflicts million of sufferers worldwide; 10% of the global population is affected with IBS-C and about 13 million adults suffer from IBS-C in the U.S. and up to 5% to 25 % raised in the Europe.

Geographically the IBS-C drugs market is emerging in the regions of the Europe, North America, Asia- Pacific, Latin America, Middle East, Africa and rest of the world. The Europe holds the largest share in the global IBS-C drugs market; North America is the second largest in the IBS-C drugs market and APAC become the third largest market for the drugs of IBS-C. About 7% of the` APAC population is suffering from IBS-C; where China and Japan are considered to be most promising market for IBS-C drugs. China has the potential and largest market share for IBS-C drugs as compare to Japan.

On the basis of medication drugs available for IBS-C are Alosetron (lotronex), lubiprostone (Amitiza) approved for women in the U.S. whereas linzess is approved for both men and women in the U.S. and it was in the 3rd phase of development in the Japan considered as potential treatment for IBS-C; Irribow (ramosetron) drugs is also available in Japan .Most of the drugs are approved only for the U.S. making it key geographic region for IBS-C. Linaclotide is the only drugs approved in the European Union for IBS-C and it is prescribed as only once-daily for adult’s treatment.

The IBS and CI are the two common gastrointestinal disorders, which involves daytime abdominal pain, bloating, discomfort and altered bowel habits. Abdominal pain is one of the predominate symptom of IBS. It is most prevalence in below the age of 45 and twice more prevalent in women in compared to men. Easy availability of drugs in the market, adaption of efficacy and safe medication, modern dietary habits, excessive intake of high fiber and governmental support are the major contributors to the global market of the IBS drugs.